The Food and Drug Administration yesterday issued a report offering recommendations to address the opioid crisis and the role of analgesic oversight in preventing addiction, overdoses and deaths. Part of the FDA’s Overdose Prevention Framework, the report recommends that the agency: implement recommendations put forward in a 2017 National Academies for Sciences, Engineering, and Medicine report; seek congressional action to strengthen oversight of opioid analgesic approvals and advertising; and increase transparency related to decision-making for opioid analgesics. 
 
Meanwhile, the agency’s independent advisors this week unanimously recommended over-the-counter access to Narcan, a nasal spray used to reverse opioid overdoses. A final decision from FDA is expected by March 29.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention recently awarded $279 million to help state and local health departments respond to the drug overdose…
News
A record 44% of adults aged 19-30 and 28% of adults aged 35-50 reported using marijuana last year, the National Institutes of Health reported today. An…
News
The Drug Enforcement Administration will host public listening sessions Sept. 12-13 to receive additional input on whether to permit telemedicine prescribing…
Perspective
For years, many commercial health insurers treated coverage for mental health or substance use disorders (SUD) very differently than for medical and surgical…
Headline
The Substance Abuse and Mental Health Services Administration this week awarded about $48 million to support substance use disorder prevention, treatment and…
Headline
The House Energy and Commerce Health Subcommittee yesterday passed 17 health-related bills, including legislation that would reauthorize the Pandemic and All-…